Andrea Kistner


 Andrea Kistner, CPA, Partner

Ms. Kistner continues an outstanding career spanning than 20 years. Her experience includes an award winning career in finance, accounting, licensing, and management in the healthcare and business finance sectors.

In addition to her role as a general partner of Roxiticus, Ms. Kistner currently serves as a senior accounting and finance professional with Castle Creek Pharmaceuticals.    Prior to her engagement at Castle Creek, she served as CFO and Director of Finance and Administration at Recordati Rare Diseases, Inc.

Ms. Kistner served as Vice President Finance at Roxiticus portfolio company, EKR Therapeutics, Inc., a specialty pharmaceutical company focused on identifying and commercializing products to serve the needs of the acute-care hospital setting, up until its sale to Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) in June 2012. While at EKR Ms. Kistner was responsible for the company’s financial modeling, budgeting, reporting and financial planning and was a key member of the executive team involved in all aspects of the company’s business development and M&A efforts. She played a key role in the sale of the EKR business to Cornerstone Therapeutics and was responsible for the team focused on all aspects of due diligence. She also was a leader on the integration team and serves as a shareholder representative for the sellers.

Prior to joining EKR, Ms. Kistner served in a variety of senior financial management positions at technology and consumer products, life sciences, and healthcare services firms, specializing in the business and strategic planning for and management of entrepreneurial businesses. She also served as Licensing Manager at Mamiye Brothers and international licensing firm where she managed license agreements with companies including Walt Disney and others.

Ms. Kistner supports the finance and accounting teams of Roxiticus portfolio companies and is expert in building processes, policies for early stage companies and preparing growth companies for continuing capital development.   Her expertise in corporate governance, leadership and team development, audit and financial controls has resulted in portfolio company awards for Early Stage Company of the Year for EKR.